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Lymph nodes draining the site of a BCG infection respond more vigorously to a 
second antigenic stimulus (1).  The augmented response is associated with a  higher 
and more sustained state of delayed-type hypersensitivity (DTH).  I When BCG  is 
introduced systemically, the reticuloendothelial system (RES)  becomes hyperactive 
(2)  arid bestows a marked degree of nonspecific resistance to a variety of infectious 
agents (3). The BCG-infected mouse may also show  increased resistance to trans- 
plantable tumors, particularly to those with immunogenic properties  (4).  It is not 
known whether this systemic effect  of BCG is due to augmentation of the immune 
response to tumor specific antigens, as occurs in BCG stimulated lymph nodes (5), or 
results from activation of a  nonspecific effector  mechanism of the sort that confers 
increased resistance to infection. 
Since mice develop classical DTH in response to an appropriate intravenous 
dose of sheep red blood cells (SRBC)  (6), it was possible to use this measure of 
T-cell activity to  investigate the  immunological consequences of  a  systemic 
BCG infection. It seems that the T-cell blocking factors which are formed by 
the interaction of antigen and antibody (7) do not function normally in BCG- 
infected mice. In consequence, the immune response is less subject to feedback 
inhibition, and immunity (both humoral and cellular) becomes  enhanced. 
Materials and Methods 
Animals.--Specifi¢  pathogen-free, male and female mice of the CD-1 strain (Charles River 
Breeding Laboratories, Wilmington, Mass.) were used at 5 or 6 wk of age. 
Organisms.--Two  strains of Mycobacterium boris BCG, BCG Montreal  (TMC 1012) and 
BCG Pasteur  (TMC 1011), were obtained from the Trudeau mycobacterial collection (TMC) 
(8). The organisms were grown as dispersed cultures in Middlebrook's 7H9 medium containing 
Tween 80 (Difco Laboratories, Inc., Detroit,  Mich.). After 5 days' incubation, the cultures 
were frozen slowly to  --70°C and were stored at this temperature.  Dosage was based upon 
viable counts performed by plating on Middlebrook's 7H10 medium. 
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Blocking Serum.--Serum containing specific inhibitors of activated T  cells was prepared 
from mice immunized intravenously with 109 SRBC. The animals were bled after 4 days by 
heart puncture. The serum, after heating to 56  ° for 30 rain, was absorbed by incubation for 
20 rain at 37°C with an equal volume of packed SRBC. The supernate, after centrifugation, 
was referred  to as absorbed 4-day serum or AS4 (7). The batch of AS4 used in the present 
study had a hemagglutinating fiter of 1:1024 before absorption and 1:128 after absorption. 
It was sterilized by membrane  filtration (0.45 # pore size, Millipore Corp., Bedford,  Mass.) 
and was stored frozen until required. 
Other Materials and Techniques.--Preparation of SRBC,  methods of immunization and 
assay for DTH,  and method for estimating serum  hemagglutinin  fiters were  described  in 
preceding papers (1, 6-8). 
RESULTS 
The Development of DTH in Response to Intravenous  Immunization of Normal 
and BCG-Infected  Mice.--In an earlier study (6), CD-1 mice showed maximum 
T-cell activity (DTH)  on day 4  of the response to intravenous immunization 
with SRBC. The optimum sensitizing dose of 105 was sharply defined. Higher 
doses caused increasing titers of hemagglutinating antibody and a corresponding 
decrease  in  DTH  (7).  The  pattern  of  response  was  quite  different  in  mice 
which  had been  infected intravenously with  9  X  107  BCG  Montreal.  Fig.  1 
shows that vaccinated mice developed higher levels of DTH in response to large 
and widely varying doses of SRBC. 
The Persistence of T-Cell Activity in BCG-Infected  Mice.--Normal and BCG- 
infected mice were immunized with doses of SRBC  chosen from either end of 
the range that gave maximum levels of DTH  in BCG-infected mice  (Fig.  1). 
BCG  Pasteur  (107)  was  inoculated  intravenously  12  days  before  injecting 
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FIc. I. Levels of DTH present in normal (O---O) or BCG-infected mice (O--O) 4 days 
after intravenous immunization wi~h varying doses of SRBC.  Sensitization was initiated 20 
days after intravenous inoculation of 9 X  107 BCG Montreal. Means of 5 -4- SEM. 1542  MODIFYING  EFFECT  OF  BCG  ON  INDUCTION  OF  T  CELLS 
SRBC by the same route.  Fig. 2 shows that DTH was higher and  persisted 
longer in the BCG-infected mice. Although not the optimal intravenous dose 
for  sensitizing  BCG-infected animals,  the  higher  dose  (10  8)  gave  a  bigger 
differential effect because it suppressed DTH almost completely in normal mice. 
This dose was therefore used for most subsequent studies. 
Effect of Varying the Dose of BCG on the T-Cell Response to SRBC.--lt is of 
potential practical importance to determine whether the immunopotentiating 
effect of BCG depends on dose, and how long the effect lasts. Mice were there- 
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FIC.  2.  Development and decay of DTH  in normal mice  (----)  and mice infected intra- 
venously with 6  X  106 BCG Montreal (  )  12 days before intravenous sensitization with 
106 (LX, &) or 108 (o, e) SRBC. Tests for DTH were performed on the days indicated; they 
were read 24 h later. Means of 5 4-  SEM. 
fore  infected intravenously with  varying doses  of BCG.  Subgroups  of  five 
normal or BCG-infected mice were tested at weekly intervals for immunological 
responsiveness to  a  standard intravenous injection of  l0  s SRBC.  DTH  was 
measured 4 days later, but the reactions are recorded in Fig. 3 against the day 
of immunization. The highest dose of BCG caused a very prompt change in the 
level of T-cell activity generated in response to a  dose of SRBC that again 
failed to sensitize uninfected controls. The effect was not sustained, perhaps 
because  the  highest  dose  of  BCG  was  debilitating.  It  may be  significant, 
however, that mice of this group also failed to react to tuberculin during the 
phase of depressed responsiveness to SRBC. 
The somewhat aberrant behavior of the most heavily infected mice did not 
obscure  a  systematic dose-effect relationship  (Fig. 3).  T-cell  responses were G.  B.  MACKANESS,  P.  H.  LAGRANGF., AND  T.  ISHIBASHI  1543 
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FIG. 3.  The indicated doses of BCG Pasteur were injected intravenously into four groups 
of mice. At weekly intervals, five mice from each group, and from a group of untreated con- 
trois (O--O), were injected intravenously with 108 SRBC. DTH was measured 4 days later 
with a standard eliciting dose (10 s) of SRBC in one hind footpad. The results are recorded 
for each treatment group.  As expected,  no DTH occurred  in untreated controls; but high 
levels of DTH appeared in BCG-treated animals. Maximum potentiation of the T-cell re- 
sponse to SRBC  was reached  at different  times in different treatment groups, but the peak 
values were linearly related to the dose of BCG used to modify the host response. This is 
shown on the right, together with SEM for the values plotted. 
augmented sooner and reached higher peaks in mice infected with larger doses 
of BCG. Ignoring the difference in time to peak response, it can be seen from the 
regression line in Fig. 3  that a  log-linear relationship existed between dose of 
BCG and peak level of DTH. 
Additive Effects of BCG and Cydophosphamide (CY.)--Mice were infected  intravenously 
with BCG Pasteur (107). Half, and an equal number of uninfected mice, were given CY (200 
mg/kg)  10 days later. Mter another 2 days, mice of the  four  treatment groups were  sub- 
divided and immunized  (in groups of five) with varying intravenous doses of SRBC. All mice 
were tested for DTH 6 days later. In addition, the mice immunized with 109 SRBC were bled 
immediately after the reading of footpad reactions.  Hemagglutinin titers were determined on 
the pooled serum from each treatment group. 
The  effect of separate and combined treatment  with BCG and  CY,  which 
enhances T-cell activity by inhibiting antibody production (9), is compared in 
Fig. 4.  The  optimum  sensitizing dose of SRBC  in untreated  CD-1  mice was 
again  10 5,  but  the  peak level  of DTH  was  lower  than  that  recorded in  the 
previous experiments (Fig. 1) because tests were not made until day 6. By this 
time, DTH has passed its peak in normal but not in BCG-infected animals (see 
below).  The  BCG-infected  animals  again  showed  potentiation  of DTH,  but 1544  MODIFYING  EF]~ECT  OF  BCG  ON  INDUCTION  OP  T  CELLS 
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FIG.  4.  Levels of DTH  developed in response to varying intravenous  doses of SRBC by 
normal mice, mice inoculated intravenously with 107 BCG 14 days before sensitization, mice 
treated with cyclophosphamide (200 mg/kg) 2 days before sensitization, and mice given both 
forms of treatment. Means of 5 ±  SEM. The reciprocal  of the hemagglutinin titer, found on 
day 7 in pooled serum obtained from mice which received the largest  (109)  dose of SRBC, is 
given at the end of each curve. 
only with high doses of SRBC. This and other observations suggest that the 
effective antigenicity of an inoculum of SRBC may be somewhat  diminished 
at this (earlier) stage of a BCG infection. An augmented T-cell response  was 
nonetheless apparent. It was accompanied by increased antibody production, as 
evidenced by the hemagglutinin  titers recorded at the end of each curve  in 
Fig. 4. 
As reported elsewhere (9), CY interferes with T-cell blocking by suppressing 
antibody formation. Its contrasting effects on DTH and antibody formation 
were seen again in the data of Fig. 4. When combined with BCG, CY caused a 
further  agumentation  of the  T-cell response.  The reason  for  this  enormous 
increase in T-cell activity is revealed by the hemaggtutinin titers found in the 
pooled serum of the mice which were immunized with  109 SRBC and bled on 
day 7: antibody formation was markedly elevated in BCG-infected animals; 
but whether infected with BCG or not, CY-treated mice failed to give a humoral 
response. G.  B.  MACKANESS,  P.  H.  LAGRANGE,  AND  T.  ISHIBASHI  1545 
In an  experiment  of similar  design,  the  separate  and  combined effects of 
BCG and  CY on the response  to  108 SRBC were studied  over an  extended 
time-course. The results recorded in Fig. 5 show that DTH appeared fleetingly 
in untreated mice, but that a high and long-lasting state of DTH developed in 
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FIG. 5. Development and persistence of DTH in response to intravenous immunization 
with 10  s SRBC by untreated mice, mice treated with CY (200 mg/kg) on day --2, mice in- 
fected intravenously  with 107 BCG Pasteur on day --14, and mice given both forms  of treat- 
ment. Means of 5 :t: SEM. 
all  treated animals. Two phases of hypersensitivity were apparent: an intense 
but  short-lived  hypersensitivity  that  gave  way  within  10  days  to  a  more 
sustained but lower level  of reactivity. Fig. 6 gives an indication of the mag- 
nitude of the DTH reactions elicited in mice treated with BCG and CY. The 
reaction  depicted  was 48  h  old.  Persistent  swelling  is  a  feature  of reactions 
elicited in CY-treated mice (10). 
BCG-Induced  Resistance  to  T-Cell  Blocking.--It  has  been  inferred  that 
DTH fails to develop or quickly disappears in animals immunized with large 1546  MODIFYING  EFFECT  OF  BCG  ON  INDUCTION  OF  T  CELLS 
Fla. 6.  Footpad reaction 48 h after injecting eliciting dose of SRBC on day 6 in mouse of 
experiment recorded in Fig. 5. It had received BCG and CY. Mice of this group had a mean 
recorded increase in footpad thickness of 24 4- 0.9 at 24 h. When the reaction was photo- 
graphed at 48 h, the difference  in thickness between right and left footpads was 15 (= 1.5 ram). 
The edema which characterizes such severe reactions involves the whole extremity. 
doses of antigen because activated T cells become blocked by immune complexes 
(7,  9).  Inasmuch as  DTH  develops in BCG-infected mice  despite very high 
levels of serum antibody, and as  CY further  enhances the T-cell activity of 
BCG-infected mice (Figs. 4, 5), the same blocking mechanism must operate, to 
some extent at least, in BCG-infected animals. If so,  the high levels of DTH 
developed by BCG-infected mice could be due as much to increased production 
of activated T  cells (1) as to the absence of blocking by immune complexes. To 
investigate this question, the inhibitory activity of serum containing blocking 
factors was compared in normal and BCG-infected animals. 
AS4 (7) was tested for its capacity to block both the induction and expression of DTH. 
Blocking of induction was tested in normal and BCG-infected mice which had received 10  7 
BCG Pasteur intravenously 12 days previously. The sensitizing inoculum of 10 s SRBC was 
given in one hind footpad to untreated mice and to mice given a single intravenous dose of 
AS4 (0.2 ml) at the time of sensitization. Others received three doses (each of 0.2 ml) of AS4 
which were given 12 h before, with, and 12 h after sensitization. DTH was tested in the op- 
posite footpad 5 days after sensitization. 
The capacity of AS4 to interfere with the expression of DTH was compared in normal and G.  B.  MACKANESS~ P.  H.  LAGRANGE,  AND  T.  ISHIBASHI  1547 
BCG-infected mice which had also been infected with l0  T BCG Pasteur 12 days before the 
sensitizing footpad inoculation of 10 a SRBC. DTH was measured 5 days after sensitization in 
untreated mice and in mice treated with 0.2 ml of normal mouse serum (absorbed with SRBC) 
or AS4 given intravenously 1 h before footpad testing. 
Fig. 7 shows that absorbed immune serum (AS4),  which completely blocked 
the induction of DTH in normal mice, did not interfere with its development 
in  BCG-infected mice.  Even  three  doses given  at 12-h  intervals  had  little 
effect. The blocking serum also interfered, but to a less extent, with an estab- 
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FIG. 7.  Left: Effect of AS4 on the induction of DTH to SRBC in  normal or BCG-i.fected 
mice.  DTH was measured  5 days after a footpad sensitizing dose of 10  8 SRBC in animals 
(NS) given 0.2 ml of normal mouse serum absorbed with an equal volume of SRBC and in 
similar animals which had received one (1 X  AS4) or 3 (3 X  AS4) doses (0.2 ml) of AS4. The 
latter were given intravenously 12 h before, together with, and 12 h after the sensitizing dose 
of SRBC. Means of 5 4- SEM. Right: Effect of AS4 (0.2 ml) on established DTH in normal or 
BCG-infected mice. BCG was given intravenously 12 days before a sensitizing footpad injec- 
tion of SRBC  (108). Footpad tests for DTH were performed 5 days after sensitization. Con- 
trols received 0.2 ml of normal serum (NS) which was also absorbed with SRBC. Means of 
5 4- SEM. 
lished state of hypersensitivity. It caused average falls of 72%  and  21%  in 
normal and BCG-infected mice, respectively (P ~  0.025). 
Effect of Systemic BCG on a Regional Response to SRBC.  -The experiments 
recorded in Fig. 7 show that a systemic infection with BCG scarcely affected 
the  level  of  DTH  induced  by  footpad  sensitization.  Potentiated  immune 
responses are achieved with BCG only if the antigen enters lymphoid tissue 
that is under active stimulation by BCG (1).  This point, which bears on the 
mode of action of BCG, is further illustrated in Fig. 8. When BCG was injected 
into one hind footpad, it had little effect on the response to SRBC injected into 
one front footpad (Fig. 8 A). But when BCG was injected into the plantar 
surface of a rear footpad, and SRBC were introduced subcutaneously on the 1548  MODIFYING  EFFECT OF  BCG  ON  INDUCTION OF  T  CELLS 
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FIG. 8.  (A.)  Levels of DTH developed in response to l0  s SRBC injected into one front 
footpad (F) of normal mice or of mice injected 12 days previously in one rear footpad (R) with 
10  7 BCG Pasteur.  Means of 5 4- SEM.  (B.) Levels of DTH developed in response  to 10  8 
SRBC injected subcutaneously over the dorsum of one hind footpad in normal mice and in 
mice injected in the ipsilateral footpad with 10  7 BCG Pasteur  12 days earlier. Means of 5 4- 
SEM. 
dorsal  aspect of the same ankle,  a  marked potentiation  of the T-cell response 
occurred  (Fig.  8  B).  Sensitivity  was  greater  in  mice immunized  in  the  rear 
footpad  than  in mice given  an equivalent  dose  of SRBC  in a  front footpad. 
This difference in response is consistently seen and is not surprising in view of 
the sensitivity of the T-cell response to antigen dose (5) and the fact that lymph 
from the front footpad is probably shared among several lymph nodes. 
The  Effect  of  Blocking  Serum  on  Mice  Sensitized  Intravenously.--Since 
blocking serum did not interfere with the induction of DTH  in BCG-infected 
mice (Fig. 7), why should T-cell activity be increased by CY in BCG-infected 
mice (Fig. 4)? It was possible, in view of the role played by the spleen in causing 
suppression  of T  cells  (5),  that  the  specifically  activated  T  cells  formed  by 
BCG-infected mice might not be fully protected against blocking by immune 
complexes. 
Blocking of activated  T  cells by AS4 was attempted in normal and BCG-infected  mice 
given 10 7 BCG Pasteur  14 days before sensitization. Normal mice received 105 SRBC,  but 
the BCG-infected animals were given  108 SRBC  because they sometimes require a  larger 
intravenous dose of antigen to provoke a comparable immune response. Mice of both groups G.  B.  MACKAN~;SS,  P.  H.  LAGRANGE,  AND  T.  ISHIBASHI  1549 
were subdivided on day 5, one half being injected intravenously  with AS4 (0.2 ml) 1 h before 
footpad testing for DTH; those of the other group received absorbed, nonimmune mouse 
seruIIl. 
The expression of DTH was largely suppressed by AS4 in mice which had 
been sensitized to  SRBC  intravenously (Fig.  10).  Blocking also occurred in 
BCG-infected mice but was significantly less (P <  0.001). 
DISCUSSION 
While studying the tumor-suppressive effects of BCG, Old and his colleagues 
(11)  ~bserved  that simple splenectomy was sometimes as effective as BCG 
in  cau~sing tumor regression. They  thought that BCG might  "promote the 
regression  of  Sarcoma  180  by  producing  a  functional  splenectomy",  and 
suggested  that  the  phenomenon  might  be  due  to  impaired  production  of 
enhancing antibody. Lagrange et al. showed in another report  (6)  that sple- 
nectomy did modify the immune response in a way that could promote anti- 
tumor immunity: spleenless mice, being virtually unable to make antibodies, 
did not suffer from T-cell blocking when immunized intravenously with large 
doses of SRBC. They behaved, in fact, like ~Y-treatod mice, which give en- 
hanced  T-cell  responses  for  a  similar  reason  (9).  The  present  experiments 
show,  however,  that  BCG  has  an  even  greater  enhancing  effect on  T-cell 
activity, but it is accomplished without interfering with antibody production. 
Indeed, serum antibody levels, like the number of antibody producing cells in a 
regional node (1), were markedly increased by BCG (Fig. 4). There is no reason 
to suppose, therefore, that the BCG-infected spleen is functionally impaired. 
The increased resistance to tumors and the enhanced T-cell responses of BCG- 
infected mice must be due, therefore, to other causes. 
Earlier studies have shown (6, 7, 9) that the mediators of DTH are blocked early 
in the immune response by a product formed when antigen and antibody interact. 
Although there is no direct evidence implicating antigen-antibody complexes, indica- 
tions  favor them for a role as the physiological inhibitors  of  T  cells (7, 9).  They 
function to control the cellular response to T-cell-dependent antigens, making it self- 
limited. The mechanism which thus regulates the immune response dearly does not 
operate normally in BCG-infected mice, for T-cell activity and antibody production 
were both increased by BCG (Fig.  4). At  least a  partial  explanation  lies in  the 
finding that blocking factors do not inhibit T  cells effectively in the presence of a 
recent BCG infection (Figs. 7, 9). Perhaps  they are disposed of more rapidly by an 
activated RES. 
Increased blood clearance rates (2)  and enhanced resistance to nonspecific 
infections (3)  are well established features of the host response to BCG. It is 
significant, therefore, that the two forms of resistance--to nonspecific infection 
(3) and to T-cell blocking (Fig. 3)--should develop at comparable rates and to 
an extent that varies with the infecting dose of BCG. It is also significant that 
maximum enhancement of the T-cell response to SRBC and of resistance  to 1550  MODIFYING  EFFECT  OF  BCG  ON  INDUCTION OF  T CELLS 
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FIG. 9.  Effect of blocking serum (0.2 ml of AS4) on DTH established by intravenous sensiti- 
zation with 105 and l0 s SRBC  in normal and BCG-infected  mice,  respectively. The BCG 
(10  ? BCG Pasteur)  were  given  intravenously 14  days before  sensitization; and  tests for 
hypersensitivity were performed  5 days after sensitization.  AS4 was injected 1 h before the 
elicifing dose of SRBC  (10s). The difference in the degree of suppression achieved in normal 
and BCG-infected mice was significant (P  <  0.001). Means of 5 -4- SEM. 
infection were reached at different times with different doses of BCG.  This is 
because BCG grows in the mouse until the antigenic stimulus is  sufficient  to 
provoke an adequate defense, an event which occurs sooner with larger doses of 
BCG (3,  12).  Antimicrobial immunity  and stimulation of the RES  are both a 
consequence of the action of mycobacterial antigens on specifically sensitized 
tissues. It follows that  the altered T-cell responses observed  in BCG-infected 
mice are a direct consequence of the host's immunological reaction to infection. 
The mechanism whereby a  BCG  infection interferes with the action of blocking 
factors,  though  seemingly related to RES  activation, is not precisely known.  It is 
evidently not due, however, to the formation of "unblocking" antibodies (13) because 
the activated T  cells of BCG-infected mice were protected from the immediate effects 
of blocking serum administered passively (Fig. 9). The increased clearing capacity of 
the RES in BCG infected mice (2) offers a plausible explanation. If the hyperactive 
phagocytic elements of the RES were to provide an enlarged display of surface re- 
ceptors that could compete successfully for immune complexes, T  cells would be free 
to circulate in a functionally active state for longer periods of time in BCG-infected 
mice. The clearance of blocking factors from the circulation of BCG-infected mice is 
under investigation. 
The  observations of Fig. 4  suggest that BCG may act in two  ways to  po- 
tentiate  T-cell responses.  In  many  similar experiments,  BCG  and  CY  have G.  B.  MACKANESS,  P.  H.  LAGRANGE,  AND  T.  ISHIBASHI  1551 
always produced  additive  effects. If immune complexes are rapidly removed 
from the circulation of BCG-infected animals,  and this were the only reason 
for the increase in T-cell activity, one would not expect CY to raise the level of 
DTH above that  achieved in uninfected mice (Fig. 4). The fact is, however, 
that BCG and CY do have a  synergistic effect. This means that the  absolute 
output of activated T  cells must be larger than normal in BCG-infected mice. 
It is equally true,  however, that T  cells are under  some constraint in BCG- 
infected animals, otherwise CY could not lift them to an even higher plane of 
activity.  Since  CY,  given before immunization,  has very little effect on  the 
ultimate levels of cellular proliferation or of plaque4forming cell production in 
a lymph node stimulated with SRBC (9), yet permits a greatly exaggerated and 
long-sustained state of DTH when combinedwith BCG (Figs. 4, 5, 6), it  follows 
that the duration of the SRBC-specific T-cell response, and the output of acti- 
vated T  cells, must both be markedly increased by BCG. 
When studying the immunopotentiating effect of BCG on the regional response to 
SRBC (1), T-cell responses were found to increase for about 2 wk, rising in proportion 
to the rate of cell proliferation provoked by BCG in the responding node. It may be, 
therefore, that the second way in which BCG affects the immune response is through 
the facilitating effect that one immune response exerts upon another. North et al. 
(14) have shown  that the rate of cell proliferation in  the spleens  of mice infected 
intravenously with virulent tubercle bacilli also increased  for about 2 wk, so that the 
effect of BCG on the immunological  responsiveness  of the spleen is probably similar 
to that in regional lymph nodes (1), and allied to the allogenic effect (15). It must be 
admitted, however, that immune complexes formed locally in spleen  or lymph node 
might be disposed  of in situ by elements of the RES made hyperactive by BCG. In 
either case,  it is certain that one effect of BCG is strictly local,  for potentiation of 
DTH occurred only when BCG and SRBC had access to the spleen (cf. Figs.  1 and 7) 
or the same lymph node (Fig.  8). Increased resistance to blocking factors that reach 
the circulation may thus be merely a  systemic manifestation of a process that also 
occurs locally in lymphoid tissues primed with BCG. 
SUMMARY 
The  inhibition  of  activated  T  cells  by products  of  the  humoral  immune 
response  is  almost  abolished  by  systemic infection  with  BCG.  As  a  result, 
BCG-infected mice develop very high levels of delayed-type hypersensitivity 
(DTH) in response to doses of sheep red blood cells (SRBC)  that cause com- 
plete  suppression of  DTH  in  normal  mice.  This  systemic  effect of  BCG  is 
dose-dependent, and lasts for about 3 wk. Its main effect is to counteract the 
inhibition of T  cells by products of the humoral response. As a  result,  and in 
contrast  to  the  T-cell-potentiating  effects  of cyclophosphamide  (CY)  which 
depend on a  diminished production of antibodies, increased levels of DTH in 
BCG-infected mice are associated with  increased  antibody production.  Since 
BCG and CY act in different ways, their effects are additive. Very remarkable 
levels of DTH are achieved when they are used in combination. 1552  MODIFYING  EFFECT OF  BCG ON  INDUCTION OF  T CELLS 
REFERENCES 
1.  Miller, T. E., G. B. Mackaness, and P. H. Lagrange.  1973. Immunopotentiation 
of BCG. II. Modulation  of the response to sheep red cells. Y. Natl. Cancer Inst. 
51:1669. 
2.  Halpern,  B. M., G. Biozzi, C. Stiffel, and D. Mouton. 1959. Effet de la stimulation 
du  syst~me  reticulo-endoth~lial  par  l'inoculation  du  bacille  de  Calmette- 
Gu~rin sur le d~veloppement de l'epith~lioma  atypique T-8 de Gu~rin chez le 
rat. Comptes Rendus Soc. De Biologie. 1~:919. 
3.  Blanden, R. V., M. J. Lefford, and G. B. Mackaness.  1969. The host response to 
Calmette:Gu~rin  bacillus infection in mice. J. Exp. Meal. 129:1079. 
4.  Old, L. J., B. Benacerraf, D. A. Clarke, C. E. Carswell, and E. St  ockert. 1961. The 
role of the reticuloendothellal  system in the host reaction to neoplasia. Cancer 
Res. 9.1:1281. 
5.  Hawrylko,  E., and G. B. Mackaness.  1973. Immunopotentiation with BCG.  III. 
Modulation  of the response to a tumor specific antigen.  J. Natl. Cancer Inst., 
51:1677. 
6.  Lagrange, P. H., G. B. Mackaness, and T. E. Miller.  1974. Influence of dose and 
route of antigen  injection  on the immunological induction  of T  cells. Y.  Exp. 
Med. 139:528. 
7.  Mackaness, G. B., P. H. Lagrange, T. E. Miller, and T. Ishibashi.  1974. Feedback 
inhibition of specifically sensitized lymphocytes. J. Exp. Med. 139:543. 
8.  Mackaness, G. B., D. J. Auclair, and P. H. Lagrange.  1973. Immunopotentiation 
with BCG. I. The immune response to different  strains  and preparations.  J. 
Natl. Cancer Inst. 51:1655. 
9.  Lagrange, P. H., G. B. Mackaness, and T. E. Miller. 1974. Potentiation of T-cell- 
mediated  immunity  by  selective  suppression  of  antibody  formation  with 
cyclophosphamide. J. Exp. Med. 139:1529. 
10.  Turk, J. L., D. Parker,  and L. W. Poulter.  1972. Functional aspects of the selec- 
tive depletion of lymphoid tissue by cyclophosphamide. Immunology.  23:493. 
11.  Old, L. J., D. A. Clarke,  B. Benacerraf,  and E. Stockert.  1962. Effect  of prior 
splenectomy  on the growth of Sarcoma  180 in normal and bacillus Calmette- 
Gu~rin infected mice. Separatum  Experientia.  18:335. 
12.  Lefford, M. J., and D. D. McGregor. 1973. The effect of anti-tuberculosis  chemo- 
therapy on immunity to tuberculosis. Immunology.  In press. 
13.  Bansal,  S.  C., and Sj~Sgren, H. O.  1972. Counteraction of the blocking of cell- 
mediated  tumor immunity by inoculation of unblocking sera and splenectomy: 
immunotherapeutic  effects on primary polyoma tumors in rats. Int. J. Cancer. 
9:490. 
14.  North, R. J., G. B. Mackaness, and R. W. Elliott.  1972. The histogenesis of im- 
munologically committed lymphocytes.  Cell. Immunol. 8:680. 
15.  Katz, D. H., W. E. Paul, E. A. Goidl, and B. Benacerraf.  1971. Carrier  function 
in antihapten antibody responses. III. Stimulation  of antibody synthesis  and 
facilitation  of hapten-specific  secondary  antibody responses by graft-vs.-host 
reactions. J. Exp. Med. 133:169. 